Rachel Owen

Rachel Owen is the current Vice President of Immunology at Precision for Medicine. Rachel has over ten years of experience in the field of immunology, with a focus on cancer immunotherapy.

Rachel began their career as a Consultant at Bavarian Nordic Inc., where they oversaw the technology transfer and outsourcing of clinical immunology activities to CROs. In this role, they also served on the due diligence team behind the company's $975 million partnership agreement with Bristol-Myers Squibb.

In 2014, Rachel was promoted to Associate Director at Bavarian Nordic Inc. In this role, they directed a team of ten conducting GLP-like immune monitoring assays and maintaining QA compliance for an ongoing Phase 3 clinical trial of PROSTVAC. Rachel also contributed to the study design and developed the immune monitoring/biomarker strategy for a Phase 2 clinical trial.

In their current role as VP of Immunology at Precision for Medicine, Rachel is responsible for leading the immunology group and providing strategic direction for the development of new products and services. Rachel has also been instrumental in developing novel biomarker assays and designing and implementing studies measuring PROSTVAC bioactivity.

Rachel Owen received their PhD in Immunology from UCL. Rachel then went on to earn their MSc in Immunology of Infectious Diseases from the London School of Hygiene and Tropical Medicine at the University of London. Finally, they completed their undergraduate degree with a BSc (Hons) in Biomedical Sciences from Sheffield Hallam University.

Rachel Owen works with Robert Ott - SVP, Business Operations, Jim Sperzel - VP, Biospecimen Solutions, and Megan Liles - VP, Operational Strategy. Rachel Owen reports to Chad Clark, President.